Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.92−0.40 (-4.29%)
Close on Nov 17, 2026Market cap $147.90MP/E –Yield –
Sutro Biopharma shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Sutro Biopharma's shares outstanding was 17M at Jun 30, 2026. For fiscal 2025 it was 8M, up 9.8% from the year before. The highest annual figure on record is 8M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8M | +9.8% |
| FY2024 | Dec 31, 2024 | 8M | +28.6% |
| FY2023 | Dec 31, 2023 | 6M | +18.6% |
| FY2022 | Dec 31, 2022 | 5M | +10.0% |
| FY2021 | Dec 31, 2021 | 5M | +41.6% |
| FY2020 | Dec 31, 2020 | 3M | +41.9% |
| FY2019 | Dec 31, 2019 | 2M | +298.7% |
| FY2018 | Dec 31, 2018 | 1M | +1185.6% |
| FY2017 | Dec 31, 2017 | 0M | +9.9% |
| FY2016 | Dec 31, 2016 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 17M | +94.7% |
| Q1 FY2026 | Mar 31, 2026 | 13M | +56.4% |
| Q4 FY2025 | Dec 31, 2025 | 9M | +3.2% |
| Q3 FY2025 | Sep 30, 2025 | 8M | +3.4% |
| Q2 FY2025 | Jun 30, 2025 | 9M | +4.8% |
| Q1 FY2025 | Mar 31, 2025 | 8M | +36.1% |
| Q4 FY2024 | Dec 31, 2024 | 8M | +38.9% |
| Q3 FY2024 | Sep 30, 2024 | 8M | +35.4% |
| Q2 FY2024 | Jun 30, 2024 | 8M | +34.6% |
| Q1 FY2024 | Mar 31, 2024 | 6M | +4.7% |
| Q4 FY2023 | Dec 31, 2023 | 6M | +6.8% |
| Q3 FY2023 | Sep 30, 2023 | 6M | +15.8% |
| Q2 FY2023 | Jun 30, 2023 | 6M | +28.5% |
| Q1 FY2023 | Mar 31, 2023 | 6M | +26.3% |
| Q4 FY2022 | Dec 31, 2022 | 6M | +23.3% |
| Q3 FY2022 | Sep 30, 2022 | 5M | +13.4% |
| Q2 FY2022 | Jun 30, 2022 | 5M | +1.8% |
| Q1 FY2022 | Mar 31, 2022 | 5M | +1.3% |
| Q4 FY2021 | Dec 31, 2021 | 5M | +18.0% |
| Q3 FY2021 | Sep 30, 2021 | 5M | +21.9% |
| Q2 FY2021 | Jun 30, 2021 | 5M | +45.1% |
| Q1 FY2021 | Mar 31, 2021 | 5M | +97.9% |
| Q4 FY2020 | Dec 31, 2020 | 4M | +69.9% |
| Q3 FY2020 | Sep 30, 2020 | 4M | +65.1% |
| Q2 FY2020 | Jun 30, 2020 | 3M | +38.6% |
| Q1 FY2020 | Mar 31, 2020 | 2M | +1.5% |
| Q4 FY2019 | Dec 31, 2019 | 2M | +4695.4% |
| Q3 FY2019 | Sep 30, 2019 | 2M | +4705.5% |
| Q2 FY2019 | Jun 30, 2019 | 2M | +4801.7% |
| Q1 FY2019 | Mar 31, 2019 | 2M | +4892.0% |
| Q3 FY2018 | Sep 30, 2018 | 0M | +6.7% |
| Q2 FY2018 | Jun 30, 2018 | 0M | – |
| Q1 FY2018 | Mar 31, 2018 | 0M | – |
| Q4 FY2017 | Dec 31, 2017 | 0M | – |
| Q3 FY2017 | Sep 30, 2017 | 0M | – |
See a number that looks wrong?